Cocaine reward and MPTP toxicity: Alteration by regional variant dopamine transporter overexpression

Molecular Brain Research

Volumn 73, Issue 1-2, 1999, Pages 37-49

  Donovan, David M ^a   Miner, Lucinda L ^a   Perry, Michael P ^a   Revay, Randal S ^a   Sharpe, Lawrence G ^a   Przedborski, Serge ^e   Kostic, Vladimir ^e   Philpot, Rex M ^f   Kirstein, Cheryl L ^f   Rothman, Richard B ^c   Schindler, Charles W ^b   Uhl, George R ^a,d  

^a Intramural Research Program   (United States)

^b Intramural Res Prog Natl I   (United States)

^c Clinical Psychopharmacology Section   (United States)

^d JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e Och Spine at New York Presbyterian Hospitals   (United States)

^f UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

Cocaine; Conditioned place preference; Dopamine transporter; Drug reward; MPTP; Transgenic mice

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; COCAINE; COMPLEMENTARY DNA; DOPAMINE; DOPAMINE TRANSPORTER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONDITIONED REFLEX; CONTROLLED STUDY; DOPAMINE UPTAKE; ENZYME ANALYSIS; GENE LOCUS; HABITUATION; LOCOMOTION; NERVE DEGENERATION; NEUROPATHOLOGY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; REWARD; SUBSTANCE ABUSE; TRANSGENIC MOUSE;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; 3,4-DIHYDROXYPHENYLACETIC ACID; ANIMALS; BEHAVIOR, ANIMAL; CARRIER PROTEINS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; COCAINE; CORPUS STRIATUM; DOPAMINE; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; FEMALE; GENE EXPRESSION REGULATION; HOMOVANILLIC ACID; HYDROXYINDOLEACETIC ACID; MALE; MEMBRANE GLYCOPROTEINS; MEMBRANE TRANSPORT PROTEINS; MICE; MICE, INBRED STRAINS; MICE, TRANSGENIC; MOTOR ACTIVITY; MPTP POISONING; NERVE TISSUE PROTEINS; PROMOTER REGIONS (GENETICS); RATS; RECOMBINANT FUSION PROTEINS; REWARD; SEROTONIN; SUBSTANTIA NIGRA; TRANSGENES; TYROSINE 3-MONOOXYGENASE; VARIATION (GENETICS);

ANIMALIA; MURINAE; MUS MUSCULUS; PARKINSONIA;

EID: 0032721505     PISSN: 0169328X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-328X(99)00235-1     Document Type: Article

References (65)

1. Banerjee S.A., Hoppe P., Brilliant M., Chikaraishi D.M. 5′ flanking sequences of the rat tyrosine hydroxylase gene target accurate tissue-specific, developmental, and transsynaptic expression in transgenic mice. J. Neurosci. 12:1992;4460-4467.
2. Belej T., Manji D., Sioutis S., Barros H.M., Nobrega J.N. Changes in serotonin and norepinephrine uptake sites after chronic cocaine: pre- vs. post-withdrawal effects. Brain Res. 736:1996;287-296.
3. Blakely R.D., De Felice L.J., Hartzell H.C. Molecular physiology of norepinephrine and serotonin transporters. J. Exp. Biol. 196:1994;263-281.
4. B. Bunow, G. Knott, MLAB, A Mathematical Modeling Laboratory, MLAB Reference Manual, Civilized Software, Bethesda, MD, 1992.
5. Cadoret R.J., Troughton E.O., Gorman T., Heywood E. An adoption study of genetic and environmental factors in drug abuse. Arch. Gen. Psychiatry. 43:1987;1131-1136.
6. G.D. Carr, H.C. Fibiger, A.G. Phillips, Conditioned place preference as a measure of drug reward, in: Neuropharmacological Basis of Reward, Oxford, NY, 1984, pp. 264-319.
7. M.G. Caron, Probing the physiological roles of dopamine in mice lacking the dopamine transporter. 27th Annual Meeting, Society for Neuroscience, New Orleans, Abstract 544, 1997, 123.
8. Cook E.H., Stein M.A., Krasowski M.D., Cox J., Olkon D.M., Kieffer J.E. Association of attention-deficit disorder and the dopamine transporter gene. Am. J. Hum. Genet. 56:1995;993-998.
9. Crabbe J.C., Belknap J.K., Buck K.J. Genetic animal models of alcohol and drug abuse. Science. 264:1994;1715-1723.
10. Crawley J.N., Belknap J.K., Collins A., Crabbe J.C., Frankel W., Henderson N., Hitzemann R.J., Maxson S.C., Miner L.L., Silva A.J., Wehner J.M., Wynshaw-Boris A., Paylor R. Behavioral phenotypes of inbred mouse strains: implications and recommendations for molecular studies. Psychopharmacology. 132:1997;107-124.
11. Drago J., Gerfen C.R., Lachowicz J.E., Steiner H., Hollon T.R. Altered striatal function in a mutant mouse lacking D1A dopamine receptors. Proc. Natl. Acad. Sci. U.S.A. 91:1994;12564-12568.
12. Forno L.S. Neuropathology of Parkinson's disease. J. Neuropathol. Exp. Neurol. 55(3):1996;259-272.
13. Freed C., Revay R., Vaughan R.A., Kriek E., Grant S., Uhl G.R. Dopamine transporter immunoreactivity in rat brain. J. Comp. Neurol. 359:1995;340-349.
14. Gelernter J., Kranzler H.R., Satel S.L., Rao P.A. Genetic association between dopamine transporter protein alleles and cocaine-induced paranoia. Neuropharmacology. 11:1994;195-200.
15. Giros B., El Mestikawy S., Bertrand L., Caron M.C. Cloning and functional characterization of a cocaine-sensitive dopamine transporter. FEBS Lett. 295:1991;149-154.
16. Giros B., Jaber M., Jones S.R., Wightman R.M., Caron M.G. Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporter. Nature. 379:1996;606-612.
17. 2 receptor, tyrosine hydroxylase and calbindin immunoreactivity. J. Comp. Neurol. 362(3):1995;400-410.
18. Harrington C.A., Lewis E.J., Krzemien D., Chikaraishi D.M. Identification and cell type specificity of the tyrosine hydroxylase gene promoter. Nucleic Acids Res. 15:1987;2363-2384.
19. Hill S.Y., Cloninger C.R., Ayre F.R. Independent familial transmission of alcoholism and opiate abuse. Alcohol.: Clin. Exp. Res. 1:1977;335-342.
20. Iverson L.L., Glowinski J. Regional studies of catecholamines in the rat brain. J. Neurochem. 13:1966;671-682.
21. Jackson-Lewis V., Jakowec M., Burke R.E., Przedborski S. Time course and morphology of dopaminergic neuronal death caused by the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Neurodegeneration. 4:1995;257-269.
22. Javitch J.A., D'Amato R.J., Strittmatter S.M., Snyder S.H. Parkinsonism-inducing neurotoxin, N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: uptake of the metabolite N-methyl-4-phenylpyridinium by dopamine neurons explain selective toxicity. Proc. Natl. Acad. Sci. U.S.A. 82:1985;2173-2177.
23. Javitch J.A., Uhl G.R., Snyder S.H. Parkinsonism-inducing neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: characterization and localization of receptor binding sites in rat and human brain. Proc. Natl. Acad. Sci. U.S.A. 81:1984;4591-4595.
24. Kitayama S., Shimada S., Xu H., Markham L., Donovan D.M., Uhl G.R. Dopamine transporter site-directed mutations differentially alter substrate transporter and cocaine binding. Proc. Natl. Acad. Sci. U.S.A. 89:1992;7782-7785.
25. + transport. Synapse. 15:1993;58-62.
26. Lazzarini A.M., Myers R.H., Zimmerman T.R. Jr., Mark M.N., Golbe L.I., Sage J.I., Johnson W.G., Duvoisin R.C. A clinical genetic study of Parkinson's disease: evidence for dominant transmission. Neurology. 44:1994;499-506.
27. LeMoal M., Simon H. Mesocortical dopaminergic network: functional and regulatory roles. Physiol. Rev. 71:1991;123-155.
28. Lowry O.H., Rosenbrough N.H., Farr A.L., Randall P.J. Protein measurement with the Folin phenol reagent. J. Biol. Chem. 193:1951;265-275.
29. Marder K., Tang M.-X., Mejia H., Alfaro B., Cote L., Louis E., Groves J., Mayeux R. Risk of Parkinson's disease among first-degree relatives. Am. Acad. Neurol. 47:1996;155-166.
30. Marttila R.J., Kaprio J., Kosenvuo M., Rinne U.K. Parkinson's disease in a nationwide twin cohort. Neurology. 38:1988;1217-1219.
31. McGonigle P., Neve K.A., Molinoff P.B. A quantitative method of analyzing the interaction of slightly selective radioligands with multiple receptor subtypes. Mol. Pharmacol. 30:1986;329-337.
32. Miner L.L., Drago J., Chamberlain P.M., Donovan D., Uhl G.R. Retained cocaine conditioned place preference in D1 receptor deficient mice. Neuroreport. 6:1995;2314-2316.
33. Miner L.L., Marley R.J. Chromosomal mapping of loci influencing sensitivity to cocaine-induced seizures in BXD recombinant inbred strains of mice. Psychoparmacology. 117:1995;62-66.
34. Miner L.L., Marley R.J. Chromosomal mapping of the psychomotor stimulant effects of cocaine in BXD recombinant inbred mice. Psychopharmacology. 122:1995;209-214.
35. Munson P.J., Rodbard D. LIGAND: a versatile computerized approach for characterization of ligand-binding systems. Anal. Biochem. 107:1980;220-239.
36. Nirenberg M.J., Chan J., Liu Y., Edwards R.H., Pickel V.M. Ultrastructural localization of the vesicular monoamine transporter-2 in midbrain dopaminergic neurons: potential sites for somatodendritic storage and release of dopamine. J. Neurosci. 16:1996;4135-4145.
37. Payami H., Larsen K., Bernard S., Nutt J. Increased risk of Parkinson's disease in parents and siblings of patients. Ann. Neurol. 36:1994;659-661.
38. Persico A.M., Reich S., Henningfield J.E., Kuhar M.J., Uhl G.R. Parkinsonian patients report blunted subjective effects of methylphenidate. Exp. Clin. Psychopharmacol. 6(1):1998;54-63.
39. Peterson G.L. A simplification of the protein assay method of Lowry et al. which is more generally applicable. Anal. Biochem. 83:1977;346-356.
40. Pettit H.O., Ettenberg A., Bloom F.E., Koob G.F. Destruction of dopamine in the nucleus accumbens selectively attenuates cocaine but not heroin self-administration in rats. Psychopharmacology. 84:1984;167-173.
41. Pifl C., Giros B., Caron M.G. Dopamine transporter expression confers cytotoxicity to low doses of the Parkinsonism-inducing neurotoxin 1-methyl-4-phenylpyridinium. J. Neurosci. 13:1993;4246-4253.
42. Platel A., Jaifre M., Pawelec C., Roux S., Porolt R.D. Habituation of exploratory activity in mice: effects of combinations of piracetam and choline on memory processes. Pharmacol. Biochem. Behav. 21:1984;209-212.
43. Platel A., Porsolt R.D. Habituation of exploratory activity in mice: a screening test for memory enhancing drugs. Psychopharmacology. 78:1992;346-352.
44. Przedborski S., Jackson-Lewis V., Yokoyama R., Shibata T., Dawson V.L., Dawson T.M. Role of neuronal nitric oxide in MPTP (1-methyl-4-phenyl-1,2,3,6 tetrahydropyridine) induced dopaminergic neurotoxicity. Proc. Natl. Acad. Sci. U.S.A. 93:1996;4565-4571.
45. Przedborski S., Kostic V., Jackson-Lewis V., Naini A.B., Simonetti S., Fahn S., Carlson E., Epstein C.J., Cadet J.L. Transgenic mice with increased Cu/An-superoxide dismutase activity are resistant to N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity. J. Neurosci. 12:1992;1658-1667.
46. Przedborski S., Levivier M., Raftopoulos C., Naini A.B., Hildebrand J. Peripheral and central pharmacokinetics of apomorphine and its effect on dopamine metabolism in humans. Mov. Disord. 10:1995;28-36.
47. Reith M.E., Meisler B.E., Sershen H., Lajtha A. Structural requirements for cocaine congeners to interact with dopamine and serotonin uptake sites in mouse brains and to induce stereotyped behavior. Biochem. Pharmacol. 35:1986;1123-1129.
48. Ritz M.C., Lamb R.J., Goldberg S.R., Kuhar M.J. Cocaine receptors on dopamine transporters are related to self-administration of cocaine. Science. 237:1987;1219-1223.
49. Roberts D.C.S., Corcoran M.E., Fibiger H.C. On the role of ascending catecholamine systems in intravenous self-administration of cocaine. Pharmacol. Biochem. Behav. 6:1997;615-620.
50. Roberts D.C.S., Koob G.F. Description of cocaine self-administration following 6-hydroxydopamine lesions of the ventral tegmental area in rats. Pharmacol. Biochem. Behav. 17:1982;901-904.
51. Rocha B.A., Fumagalli F., Gainetdinov R.R., Jones S.R., Ator R., Giros B., Miller G.W., Caron M.G. Cocaine self-administration in dopamine-transporter knockout mice. Nat. Neurosci. 1:1998;132-137.
52. Rodbard D., Lenox R.H., Wray H.L., Ramseth D. Statistical characterization of the random errors in the radioimmunoassay dose-response variable. Clin. Chem. 22:1976;350-358.
53. Rothman R.B. Analysis of binding surfaces: a methodology appropriate for the investigation of complex receptor mechanisms and multiple neurotransmitter receptors. Neuropeptides. 4:1983;41-44.
54. Rothman R.B. Binding surface analysis: an intuitive yet quantitative method for the design and analysis of ligand binding studies. Alcohol Drug Res. 6:1986;309-325.
55. 3H] cycloFOXY binding in rat brain: further evidence that beta-FNA alkylates the opioid receptor complex Synapse. 8:1991;86-99.
56. 125I] RTI-55 J.P.E.T. 274:1994;385-395.
57. Rovati G.E., Rodbard D., Munson P.J. DESIGN: computerized optimization of experimental design for estimating Kd and Bmax in ligand binding experiments: II. Simultaneous analysis of homologous and heterologous competition curves and analysis blocking and of "multiligand" dose-response surfaces. Anal. Biochem. 184:1990;172-183.
58. 123/125I] RTI-55, an in vivo label for the serotonin transporter Synapse. 11:1992;134-139.
59. Shimada S., Kitayama S., Lin C.-L., Patel A., Nanthakumar E., Gregor P., Uhl G.R. Cloning and expression of a cocaine sensitive dopamine transporter cDNA. Science. 254:1991;576-578.
60. Uhl G.R. Parkinson's disease: neurotransmitter and neurotoxin receptors and their genes. Eur. J. Neurol. 30:1990;21-30. Suppl. 1.
61. Uhl G.R. Hypothesis: the role of dopaminergic transporters in selective vulnerability of cells in Parkinson's disease. Ann. Neurol. 43(5):1998;555-560.
62. G.R. Uhl, G.I. Elmer, M.C. LaBuda, R.W. Pickens, Genetic influences in drug abuse, in: F.E. Bloom, D.J. Kupfer (Eds.), Psychopharmacology, The Fourth Generation of Progress, Raven Press, New York, 1995, pp. 1793-1806.
63. Wise R.A., Rompre P.P. Brain dopamine and reward. Annu. Rev. Psychol. 40:1989;191-225.
64. Wooten G.F., Currie L.J., Bennett J.P., Harrison M.B., Trugman J.M., Parker W.D. Jr. Maternal inheritance in Parkinson's disease. Am. Neuro. Association. 41(2):1997;265-268.
65. Xu M., Thu X., Cooper D.C., Moratalla R., Graybiel A.M., White F.J., Tonegawa S. Elimination of cocaine-induced hyperactivity and dopamine-mediated neurophysiological effects in dopamine D1 receptor mutant mice. Cell. 79:1994;945-955.